In summary, LLC is a highly aggressive, poorly immunogenic tumor model unresponsive to most immunotherapies.22 By combining single-dose RT with two distinct immunotherapies with non-redundant mechanisms, the immunogenicity of LLC tumors was enhanced, with increased infiltration of activated NK and CD8+ T cells and decreased T cell exhaustion and tumor-infiltrating Tregs, achieving curative responses. This evidence concerns the gene CD8A and neoplasm.